PatentJul 20, 2026, 07:57 AM
Clearmind Files Hong Kong Patent for PTSD Psychedelic Compounds
AI Summary
Clearmind Medicine Inc. announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds aimed at treating Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. This filing is part of Clearmind's exclusive worldwide licensing agreement with Yissum Research Development Company. The company views this as a strategic move to access the Asian market, which is part of a global PTSD treatment market valued at $18.5 billion in 2025 and projected to reach $30.2 billion by 2035.
Key Highlights
- Filed a patent application with the Hong Kong Patent Office for psychedelic compounds.
- Compounds target Post-Traumatic Stress Disorder (PTSD) and other mental health disorders.
- The filing is part of an exclusive worldwide licensing agreement with Yissum Research Development Company.
- Global PTSD treatment market valued at approximately $18.5 billion in 2025.
- Market projected to reach $30.2 billion by 2035, growing at a CAGR of 5.0%.
- Strengthens Clearmind's global IP portfolio and provides strategic access to the Asian market.
- Company's intellectual portfolio currently consists of 19 patent families, including 32 granted patents.
Price Impact
More from CMND